JP2010523682A - 癌及び他の疾患の治療に有用なカルボリン誘導体の投与 - Google Patents

癌及び他の疾患の治療に有用なカルボリン誘導体の投与 Download PDF

Info

Publication number
JP2010523682A
JP2010523682A JP2010503086A JP2010503086A JP2010523682A JP 2010523682 A JP2010523682 A JP 2010523682A JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010523682 A JP2010523682 A JP 2010523682A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
alkoxy
aryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523682A5 (enExample
Inventor
カオ リアングクイアン
ヒラワト サミト
ミルレル ラングドン
エル．エルフリング ガリ
ダビス トホマス
エル．ウエエタルル マリア
Original Assignee
ピーティーシー セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス，インコーポレーテッド filed Critical ピーティーシー セラピューティクス，インコーポレーテッド
Publication of JP2010523682A publication Critical patent/JP2010523682A/ja
Publication of JP2010523682A5 publication Critical patent/JP2010523682A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010503086A 2007-04-13 2008-04-12 癌及び他の疾患の治療に有用なカルボリン誘導体の投与 Pending JP2010523682A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91161207P 2007-04-13 2007-04-13
PCT/US2008/004809 WO2008127714A1 (en) 2007-04-13 2008-04-12 Administration of carboline derivatives useful in the treatment of cancer and other diseases

Publications (2)

Publication Number Publication Date
JP2010523682A true JP2010523682A (ja) 2010-07-15
JP2010523682A5 JP2010523682A5 (enExample) 2011-10-20

Family

ID=39618825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503086A Pending JP2010523682A (ja) 2007-04-13 2008-04-12 癌及び他の疾患の治療に有用なカルボリン誘導体の投与

Country Status (6)

Country Link
US (1) US20100158858A1 (enExample)
EP (1) EP2139476A1 (enExample)
JP (1) JP2010523682A (enExample)
AU (1) AU2008239598A1 (enExample)
CA (1) CA2683444A1 (enExample)
WO (1) WO2008127714A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503065A (ja) * 2007-11-08 2011-01-27 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
JP2012528192A (ja) * 2009-05-27 2012-11-12 ピーティーシー セラピューティクス，インコーポレーテッド がん及び非新生物性状態の治療方法
WO2017073743A1 (ja) * 2015-10-30 2017-05-04 協和発酵キリン株式会社 三環性化合物
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200608176B (en) * 2004-03-15 2008-05-28 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
WO2010138695A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
TW201100419A (en) 2009-05-27 2011-01-01 Ptc Therapeutics Inc Processes for the preparation of substituted tetrahydro beta-carbolines
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
WO2010138659A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
DK3004090T3 (en) 2013-05-28 2018-01-08 Astrazeneca Ab CHEMICAL COMPOUNDS
US10307406B2 (en) 2013-08-31 2019-06-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
CN112375078B (zh) 2014-12-18 2023-12-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
WO2018115984A1 (en) 2016-12-19 2018-06-28 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
IL278063B2 (en) 2018-06-21 2025-08-01 Hoffmann La Roche Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
MX2021001364A (es) 2018-08-03 2021-04-13 Ptc Therapeutics Inc Formas farmaceuticas orales biodisponibles.
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
BR112021013913A2 (pt) 2019-01-15 2021-09-21 Ptc Therapeutics, Inc. Método para tratar uma leucemia mieloide aguda
US11278532B2 (en) 2019-08-06 2022-03-22 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
KR20250031230A (ko) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113703A2 (en) * 2005-04-18 2006-10-26 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US254878A (en) * 1882-03-14 Train-boat
US282849A (en) * 1883-08-07 Fruit-jar
US40527A (en) * 1863-11-03 Improvement in cooking-stoves
US64683A (en) * 1867-05-14 mason and joseph messinger
US272759A (en) * 1883-02-20 Desk-top
WO2002011705A2 (en) * 2000-08-09 2002-02-14 Pharmacia Italia Spa Composition for combined use of aromatase inhibitors
MXPA03007142A (es) * 2001-02-12 2004-05-24 Lilly Icos Llc Derivados de carbolina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113703A2 (en) * 2005-04-18 2006-10-26 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503065A (ja) * 2007-11-08 2011-01-27 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
JP2014205690A (ja) * 2007-11-08 2014-10-30 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための医薬組成物
JP2016104767A (ja) * 2007-11-08 2016-06-09 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
JP2012528192A (ja) * 2009-05-27 2012-11-12 ピーティーシー セラピューティクス，インコーポレーテッド がん及び非新生物性状態の治療方法
US11613538B2 (en) 2009-05-27 2023-03-28 Ptc Therapeutics, Inc. Method of inhibiting or reducing a viral infection
WO2017073743A1 (ja) * 2015-10-30 2017-05-04 協和発酵キリン株式会社 三環性化合物
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers

Also Published As

Publication number Publication date
CA2683444A1 (en) 2008-10-23
US20100158858A1 (en) 2010-06-24
EP2139476A1 (en) 2010-01-06
AU2008239598A1 (en) 2008-10-23
WO2008127714A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
JP2010523682A (ja) 癌及び他の疾患の治療に有用なカルボリン誘導体の投与
WO2008127715A1 (en) Carboline derivatives useful in the treatment of cancer and other diseases
JP4857452B2 (ja) 血管新生の抑制に有用なカルボリン誘導体
US8372860B2 (en) Carboline derivatives useful in the inhibition of angiogenesis
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
US8697662B2 (en) Methods for treating Kaposi sarcoma
RU2640485C2 (ru) Комбинированное лечение рака
EP1732543B1 (en) Tetracyclic carboline deratives for inhibiting angiogenesis
US20100173873A1 (en) Treatment of metastasized tumors
US8299081B2 (en) Methods for treating drug resistant cancer
JP2026507092A (ja) 健康状態の治療のための小分子を作製および使用するための組成物および方法
TW200524595A (en) Methods for treating IGF1R-inhibitor induced hyperglycemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140218